KRAS Q61 NSCLC: When Alleles Matter.
Where this comes from
- Record sourced from PubMed, PMID 42720996.
- Also identified by DOI 10.1158/1078-0432.CCR-26-2135.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent article provides the largest characterization to date of KRAS Q61-mutant NSCLC. The findings reveal clinically relevant differences between Q61 alleles and highlight the importance of interpreting KRAS mutations within their genomic context. As RAS-directed therapies evolve, understanding this heterogeneity becomes increasingly relevant for patient stratification and therapeutic development.